Genotype tailoring of antiplatelet therapy provides no benefit: PCI study

One of the largest trials to investigate a CYP2C19 genotype-guided strategy to guide antiplatelet choice has found no benefit when applied to clopidogrel and ticagrelor after PCI. The TAILOR-PCI study, which enrolled 5,302 patients requiring 12 months of antiplatelet therapy after PCI, failed to show any benefit from selecting therapy based on the presence of ...

Already a member?

Login to keep reading.

© 2021 the limbic